Investigating the role of specific neutrophils in influenza outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to compare the percentage of CXCR4-expressing neutrophils in the blood of influenza survivors and non-survivors. It focuses on understanding the role of these neutrophils in the immune response to influenza, particularly in patients with acute respiratory distress syndrome. Blood samples and bronchoalveolar lavage (BAL) will be collected within 24 hours and on day 3 after ICU admission to analyze neutrophil populations using immunostaining and flow cytometry. The study will also track mortality rates at 28 and 90 days post-admission.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged 18 yo or above.
* Acute respiratory distress syndrome as defined by the Berlin classification.
* Invasive mechanical ventilation for less than 24 hours.
* Cause of ARDS:

  * Influenza infection proven by polymerase chain reaction OR
  * Bacterial infection (tracheal aspirate with more than 105 CFU/mL and BAL with more than 104 CFU/mL.
  * Pancreatitis according to the 2013 Working Group IAP/APA Acute Pancreatitis Guidelines.
  * Peritonitis according to the 2018 SFAR guidelines.
* Health insurance.
* Written informed consent from legal relative or representative.

Exclusion Criteria:

* Neutropenia (\< 500/mm3)
* Neutrophils qualitative defect.
* Patient included in an interventional research assessing an immunomodulatory or antiviral drug.
* Acquired ImmunoDeficiency Syndrome.
* Contraindication to BAL:

  * Severe bronshospasm.
  * Out-of-control shock.
  * Intracranial high pressure.
  * Refractory hypoxemia (PaO2/FiO2 \< 60 mmHg).
* Legal restriction: prisoners, pregnancy, legal protection.

Where it's running

• Hopital Pellegrin
  Bordeaux, France Recruiting
• Hopital Haut-Lévêque
  Pessac, France Not yet recruiting

Study contacts

• Study coordinator: Renaud PREVEL, Dr
• Email: renaud.prevel@u-bordeaux.fr
• Phone: 5 57 87 26 26

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Abbott ID NOW at the point of care for flu-like illness in long-term care facilities

  This trial tests whether the Abbott ID NOW rapid test at the point of care in long-term care facilities can help identify influenza sooner for residents 65 and older with fever and respiratory symptoms.

  Recruiting China Medical University Hospital · Taichung · NCT07846423

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

• Full-Course ECMO Pathway for Moderate-to-Severe ARDS

  This study tests a standardized, full-course ECMO management pathway to see if it improves care for adults with moderate-to-severe ARDS treated with VV-ECMO in real-world Chinese centers.

  Recruiting at 15 sites Southeast University, China · Beijing and 38 other locations · NCT07726953

• Safety and PK of Ingavirin Forte vs Ingavirin in healthy adults under fasting and fed conditions

  This early-phase study tests whether Ingavirin Forte (90 mg + 20 mg) is safe and how it behaves in the body compared with Ingavirin (90 mg) in healthy adults aged 18–45, under different meal conditions.

  Recruiting Phase 1 Valenta Pharm JSC · Saint Petersburg · NCT07645534

• Light-based immune boost to help prevent viral upper respiratory infections

  A daily handheld light therapy device is tested to see if it can lower how often adults at a military medical facility get colds, flu, or other upper respiratory infections.

  Recruiting Mike O'Callaghan Military Hospital · Nellis Air Force Base, Nevada · NCT07610967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.